Muscular Dystrophy UK praises collaboration between Coronation Street and The Lily Foundation

Lockdown research, by Professor Antonella Spinazzola

Professor Antonella Spinazzola, MD, reflects on her experience of research into Mitochondrial DNA Medicine during the pandemic. What we do Research in my laboratory focuses on the parts of the cells called mitochondria, which convert most of our food into a form of energy usable by the body. We study how mitochondria are made and function,

New guidance on the safety of medicine use in people with mitochondrial myopathies

    After an international study, The IMP has released updated guidance on the medicines that should be avoided or used with caution in people with primary mitochondrial disease. The IMP is a network of mitochondrial disease patient organisations which MDUK is part of. The study, carried out by specialists, researchers and clinicians, was published in

Highlights of the 2019 Neuromuscular Translational Research Conference

The 12th UK Neuromuscular Translational Research Conference was held in Newcastle on 4-5 April 2019. Jointly organised by MDUK and the MRC Centre for Neuromuscular Disease, the conference showcased recent developments in research and was attended by eminent international scientists. The conference included talks and posters on a range of neuromuscular conditions. We were delighted to

Have your say on research into mitochondrial disease

Despite growing research activity in the UK and across the globe, many questions about mitochondrial disease have not been answered. Funding is limited, so it’s essential that it’s directed to areas that are most important. The aim of the Mitochondrial Disease Priority Setting Partnership (PSP) is to find the most important unanswered questions about mitochondrial

PREFER is looking for volunteers living with myotonic dystrophy or mitochondrial disease

As part of the IMI PREFER project, we’re working with Newcastle University to conduct focus groups for people with myotonic dystrophy type 1 or mitochondrial disease, as well as their caregivers. We want to know what people with these conditions think about different treatments (real treatments and hypothetical ones) and what trade-offs they are willing to make. A

Mitochondrial myopathy trial recruiting in the UK

Update 25 April 2019: Enrollment for this trial is now complete. Top-line data is expected by the end of 2019. Stealth BioTherapeutics has initiated a phase 3 trial (MMPOWER-3) to test elamipretide in individuals with primary mitochondrial myopathy. Elamipretide is a drug that binds to cardiolipin – an important structural component in mitochondria. Animal studies


Near you

Find support and services in your area:

Keep in touch